Specifically, sPD-L1 administration alleviated lung inflammation and improved survival in mice, indicating its potential as a therapeutic agent in COVID-19-related acute respiratory distress syndrome [25]. This evidence concerns the gene SPDL1 and acute respiratory distress syndrome.